NCT00831467

Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: CureVac · Industry
• Sex: Male
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the efficacy and safety of a new vaccine in hormone refractory prostate cancer

Detailed description

Immunotherapy of prostate cancer is a promising approach for the treatment of advanced or recurrent forms of prostate cancer. Recently, immunotherapy of prostate cancer has been facilitated by the identification of a number of prostate specific antigens that are expressed in healthy and tumor prostate tissues. For prostatectomized patients, such antigens offer ideal targets for immunotherapy as they are only present in tumor but not in healthy tissue. The use of prostate specific antigens in a cancer vaccine is one attractive option for cancer immunotherapy.

Conditions

• Hormonal Refractory Prostate Cancer

Interventions

Type	Name	Description
BIOLOGICAL	CV9103	Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.

Timeline

• Start date: 2009-01-01
• Primary completion: 2009-12-01
• Completion: 2013-09-01
• First posted: 2009-01-29
• Last updated: 2018-03-20

Locations

12 sites across 2 countries: Germany, Italy